Pi Therapeutics
Ness Ziona
About Pi Therapeutics
Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $19.7M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2019)
- Website: pi-tx.com
Industries & Categories
Biotechnology, Medical, Oncology
Canonical: https://fsome.com/organization/pi-therapeutics-117954 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.